Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data (Q33195173)

23 July 2017

Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data (English)

1 reference

23 July 2017

0 references

1 reference

2

Stephan Rössner

1 reference

23 July 2017

Kristina Elfhag

1

1 reference

PubMed ID

14627761

23 July 2017

Anna Maria Carlsson

series ordinal

3

1 reference

PubMed ID

14627761

23 July 2017

Britta Barkeling

series ordinal

4

1 reference

23 July 2017

1 November 2003

1 reference

23 July 2017

1 reference

23 July 2017

11

1 reference

23 July 2017

11

1 reference

23 July 2017

1391-1399

1 reference

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

23 July 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Sibutramine. A review of its contribution to the management of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Sibutramine produces dose-related weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Subgrouping in obesity based on Rorschach personality characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Telling more than we can know: Verbal reports on mental processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Emotion and eating in obesity? A critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Aging and terminal changes in Rorschach responses among the Japanese elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Some psychological characteristics of prostitutes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Personality differences between eating-disordered women and a nonclinical comparison sample: a discriminant classification analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

A Rorschach study of oral dependence in alcoholics and depressives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Emotional factors and subjective quality of life in subjects with spinal cord injuries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

The spectrum of behaviors influenced by serotonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Intraclass correlations: uses in assessing rater reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Pharmacological aspects of appetite: implications for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Combining behavioral and pharmacological treatments for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Predictors of weight maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Effects of Sibutramine on Binge Eating, Hunger, and Fullness in a Laboratory Human Feeding Paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

An open-label trial of sibutramine in obese patients with binge-eating disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Sibutramine reduces food intake in non-dieting women with obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Psychological and behavioral predictors of weight loss during drug treatment for obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Microstructure of eating behavior associated with Rorschach characteristics in obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Psychologic aspects in proctalgia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

A double-blind randomized placebo-controlled trial of sibutramine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

Dependency and eating disorders in female psychiatric inpatients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

7 January 2021

Oral imagery and autonomic arousal in social isolation

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

7 January 2021

Autonomic arousal, interpersonal climate, and orality

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

7 January 2021

Some extraordinary facts about obese humans and rats

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.188

7 January 2021

Identifiers

DOI

10.1038/OBY.2003.188

1 reference

23 July 2017

1 reference

PubMed ID

14627761